Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
South Korea Inflation Rises to 2.3% in December, Matching Market Expectations 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Japanese Business Leaders Urge Government Action as Weak Yen Strains Economy 
USDA $12 Billion Farm Aid Program Draws Mixed Reactions from Row Crop Farmers 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Citi Forecasts a Volatile but Ongoing Bull Market for S&P 500 in 2026 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
South Korean Won Slides Despite Government Efforts to Stabilize Currency Markets 
U.S. Dollar Steadies Ahead of Fed Minutes as Markets Eye Policy Divisions 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
Gold Prices Rebound in Europe as Geopolitical Tensions and Fed Outlook Support Bullion 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Sanofi will be acquiring mRNA developer, Translate Bio, and this was revealed on Monday, Aug. 4. The French pharmaceutical company headquartered in Paris was reported to have offered to buy the US-based company after experiencing setbacks in its attempt to produce its own brand of COVID-19 vaccine.
As per CNBC, Sanofi will purchase all the available shares of the Massachusetts-headquartered mRNA therapeutics company at $38.00 per share. The total equity value is around $3.2 billion, and it will be paid in cash.
An insider who cannot be identified because of the confidentiality of the deal shared that Translate Bio’s board will hold a meeting to discuss the offer. Another source revealed that Sanofi’s executive directors also convened last Sunday to talk about the potential acquisition.
At any rate, it was said that the boards of the two companies gave their approval for the deal. Translate Bio’s chief executive officer, and the firm’s largest shareholder are reportedly backing the takeover offer by Sanofi, and this was confirmed through a joint statement.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Sanofi’s CEO, Paul Hudson, said in a press release. “A fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space and we will also be able to accelerate our existing partnered programs already under development.”
Hudson added that with Translate Bio, aside from vaccines, Sanofi’s goal is to unravel the potential of messenger ribonucleic acid (mRNA) in other medical fields, including immunology, oncology, and rare diseases.
Prior to this recent acquisition, Sanofi and Translate Bio have actually been working together since 2018, and last year, they teamed up to develop an mRNA-based vaccine for COVID-19. In the third quarter of this year, they are expecting to get provisional results of their Phase I/II clinical trial.
Meanwhile, Reuters reported that shares of Sanofi went up by more than 70% to over $50 in extended trading. The financial terms of the French firm’s offer were not disclosed at this time, and Translate Bio's market value has also soared to around $2.2 billion at the close on Monday.
